Eight-year changes in hepatic steatosis and associated metabolic factors in a Japanese cohort of people with HIV.

Authors

Masayuki Murata, Yuji Matsumoto, Koji Takayama, Sho Yamasaki, Ken Yamamoto, Kosaku Sasaki

Published in

HIV medicine. Sep 30, 2026. Epub Sep 30, 2026.

Abstract

Hepatic steatosis is an increasingly important liver-related comorbidity among people with HIV. We evaluated longitudinal changes in hepatic steatosis over 8 years and the associated clinical factors in a single-centre Japanese cohort of people with HIV.
This single-centre retrospective cohort study included 94 people with HIV who underwent paired FibroScan assessments a median of 8.18 years apart. Hepatic steatosis was defined as a controlled attenuation parameter (CAP) ≥238 dB/m, with incident steatosis defined as CAP < 238 dB/m at baseline and CAP ≥238 dB/m at follow-up. Factors associated with incident steatosis and follow-up CAP were assessed using Firth's penalized logistic regression and an analysis of covariance (ANCOVA)-type multivariable linear model, respectively.
Median CAP increased from 232 to 282 dB/m (p < 0.001), while the prevalence of hepatic steatosis increased from 45/94 (48%) to 63/94 (67%) (p = 0.001). Of 49 participants without baseline steatosis, 24 (49%) developed incident steatosis. After adjustment for baseline CAP, greater percentage weight gain, higher baseline body mass index and triglycerides ≥200 mg/dL at follow-up were each associated with higher follow-up CAP, whereas tenofovir alafenamide (TAF) exposure during follow-up was not. Median liver stiffness measurement (LSM) did not change significantly.
CAP values and the prevalence of hepatic steatosis increased over 8 years in this single-centre Japanese cohort of people with HIV. Greater weight gain and metabolic abnormalities were associated with higher CAP at follow-up. These observational findings suggest that monitoring body weight, metabolic parameters, hepatic steatosis and liver stiffness may be useful in long-term HIV care.

PMID:
42813948
Bibliographic data and abstract were imported from PubMed on 30 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.